TG Therapeutics, Inc.

TGTX • Biotechnology

$55.98

▼ -0.73 (-1.28%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$8.81B

Growth

-15.0%

Cash Flow

0/5

Trend

Negative

Evidence

Stable or improving margins · 72.6%Positive revenue growth · 203.1%Reasonable earnings multiple · 9.62Manageable debt level · 0.4Healthy liquidity · 4.1

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$55.99

Change-1.28%

Shares Out157.28M

Market Cap$8.81B

Enterprise Value$9.00B

52W Range25.28 - 59.30

Beta1.67

P/E19.94

P/S11.01

P/B14.58

P/FCF-15,723.97

EV/Sales11.25

Price$55.99

Change-1.28%

Shares Out157.28M

Market Cap$8.81B

Enterprise Value$9.00B

52W Range25.28 - 59.30

Beta1.67

P/E19.94

P/S11.01

P/B14.58

P/FCF-15,723.97

EV/Sales11.25

EV/EBITDA63.89

EV/FCF-16,068.86

Earnings Yield5.01%

FCF Yield-0.01%

Dividend Yield0.00%

Gross Margin83.66%

Oper. Margin20.01%

Profit Margin72.56%

Debt/Eq0.40

Current Ratio4.10

Quick Ratio3.29

Revenue 5Y-15.05%

Target$80.50

Target Upside43.79%

Target Median$80.50

Target Range78.00 - 83.00

Volume2.86M

Avg Volume2.53M

EPS Surprise-0.06

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

86/100

Financial Strength

Debt, cash, stability

83/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

51/100

Why this score▼

Stable or improving margins · 72.6%Positive revenue growth · 203.1%Reasonable earnings multiple · 9.62Manageable debt level · 0.4Healthy liquidity · 4.1

Analyst view

Analyst sentiment and price target

TGTX

Analyst sentiment

Based on 13 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$78.00

Mean

$80.50

Median

$80.50

High

$83.00

Company Overview

IPO: 5/3/2010

Industry: Biotechnology

P/B i: 14.58

Debt / Equity i: 0.40

Operating Margin: 20.01%

Net Margin: 72.56%

ROE i: -

ROIC: -

Financial Health

Score17 / 20

Debt / Equity: 0.40

Current Ratio: 4.10

Quick Ratio: 3.29

Status: Strong

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected

Charney Laurence N

Transaction: 06/11/2026

BUY

Change

+8,325

Price

Not reported

Filing

06/15/2026

Type

BUY

Echelard Yann

Transaction: 06/11/2026

BUY

Change

+8,325

Price

Not reported

Filing

06/15/2026

Type

BUY

Hoberman Kenneth

Transaction: 06/11/2026

BUY

Change

+8,325

Price

Not reported

Filing

06/15/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Charney Laurence N	BUY	+8,325	Not reported	06/11/2026	06/15/2026
Echelard Yann	BUY	+8,325	Not reported	06/11/2026	06/15/2026
Hoberman Kenneth	BUY	+8,325	Not reported	06/11/2026	06/15/2026
HUME DANIEL	BUY	+8,325	Not reported	06/11/2026	06/15/2026
Lonial Sagar	BUY	+8,325	Not reported	06/11/2026	06/15/2026
Charney Laurence N	SELL	-13,197	Not reported	01/29/2026	01/29/2026
Charney Laurence N	SELL	-30,000	Not reported	01/28/2026	01/29/2026
Power Sean A	BUY	+90,000	Not reported	01/08/2026	01/09/2026
WEISS MICHAEL S	BUY	+622,000	Not reported	01/08/2026	01/09/2026
Echelard Yann	SELL	-5,000	$32.57	11/24/2025	11/25/2025
WEISS MICHAEL S	SELL	-803,717	Not reported	11/05/2025	11/07/2025
Lonial Sagar	SELL	-20,852	$32.24	09/11/2025	09/12/2025
Echelard Yann	SELL	-10,000	$36.94	06/13/2025	06/16/2025
Lonial Sagar	BUY	+14,718	Not reported	06/12/2025	06/16/2025
HUME DANIEL	BUY	+14,718	Not reported	06/12/2025	06/16/2025
Hoberman Kenneth	BUY	+14,718	Not reported	06/12/2025	06/16/2025
Charney Laurence N	BUY	+21,408	Not reported	06/12/2025	06/16/2025
Echelard Yann	BUY	+14,718	Not reported	06/12/2025	06/16/2025
HUME DANIEL	SELL	-62,459	Not reported	03/17/2025	03/18/2025
Charney Laurence N	SELL	-6,000	Not reported	03/10/2025	03/11/2025

About the Company

TG Therapeutics, Inc.

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

Source - link

Peers

ACLX ALKS ARWR CRSP IMVT KRYS KYMR PCVX PTCT PTGX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.

GlobeNewsWire

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)

TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.

Seeking Alpha

235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG

Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company's stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%

Defense World

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-06	0.23	0.17	-0.06
2026-02-26	0.35	0.14	-0.21
2025-11-03	0.24	2.43	2.19
2025-08-04	0.32	0.17	-0.15
2025-05-05	0.18	0.03	-0.15
2025-03-03	0.08	0.15	0.07
2024-11-04	0.03	0.02	-0.01
2024-08-06	-0.05	0.04	0.09
2024-05-01	-0.03571	-0.07	-0.03429
2024-02-28	-0.12	-0.09	0.03
2023-11-01	0.12	0.73	0.61
2023-08-01	-0.26	-0.34	-0.08